Home > Medical Reference > Encyclopedia (English)

Toggle: English / Spanish

Ask Our Experts

Get answers to your specific medical questions from UM Medical Center experts.

Note: This is for informational purposes only. Doctors cannot provide a diagnosis via e-mail.

 

Related Content

Our Doctors

Patient Success Stories

Speciality Services

Podcasts

Membranoproliferative GN I

Alternative Names:

Mesangiocapillary glomerulonephritis (type I); Membranoproliferative glomerulonephritis (type I); Lobular GN; Glomerulonephritis - membranoproliferative (type I); MPGN type I

Treatment:

Treatment may vary according to the symptoms. Treatment goals include reduction of symptoms, prevention of complications, and slowed progression of the disorder. Steroids and cytotoxic agents have been used and may benefit certain individuals. Dipyridamole has also been used in some individuals.

Dietary adjustments may include restrictions on sodium (see sodium in diet ), fluids, protein, or other restrictions as appropriate to control high blood pressure, swelling , and accumulation of waste products in the bloodstream.

Antihypertensive medications are critical to help control blood pressure . Diuretics or other medications may be appropriate to control swelling or other symptoms.

Dialysis or kidney transplant may eventually be required to manage kidney failure. Combination therapy with aspirin and dipyridamole may slow progression to renal failure with MPGN 1. This treatment is of unproven value.

Expectations (prognosis):

The disorder progresses slowly to chronic renal failure . Fifty percent of cases will develop chronic renal failure within 10 years.

Complications:

Calling your health care provider:

Call for an appointment with your health care provider if symptoms indicate MPGN I may be present.

Call for an appointment with your health care provider if symptoms worsen or persist, or if new symptoms develop, including decreased urine output .

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

adam.com